Comyn, O;
Wickham, L;
Charteris, DG;
Sullivan, PM;
Ezra, E;
Gregor, Z;
Aylward, GW;
... Bainbridge, JW; + view all
(2017)
Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study).
Eye
, 31
(9)
pp. 1253-1258.
10.1038/eye.2017.75.
Preview |
Text
Bainbridge_Comyn et al.pdf - Accepted Version Download (488kB) | Preview |
Abstract
PURPOSE: Our aim was to evaluate the impact of intravitreal ranibizumab pretreatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure. PATIENTS AND METHODS: We performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinopathy. Seven days prior to vitrectomy surgery, participants were randomly allocated to receive either intravitreal ranibizumab (Lucentis, Novartis Pharmaceuticals UK Ltd, Frimley, UK) or subconjunctival saline (control). The primary outcome was best-corrected visual acuity 12 weeks following surgery. RESULTS: At 12 weeks, the mean (SD) visual acuity was 46.7 (25) ETDRS letters in the control group and 52.6 (21) letters in the ranibizumab group. Mean visual acuity improved by 14 (31) letters in the control group and by 24 (27) letters in the ranibizumab group. We found no difference in the progression of tractional retinal detachment prior to surgery, the duration of surgery, or its technical difficulty. Vitreous cavity haemorrhage persisted at 12 weeks in two of the control group but none of the ranibizumab group. CONCLUSION: Ranibizumab pretreatment may improve the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy by reducing the extent of post-operative vitreous cavity haemorrhage. However, the effect size appears to be modest; we calculate that a definitive study to establish a minimally important difference of 5.9 letters at a significance level of P<0.05 would require 348 subjects in each arm.
| Type: | Article |
|---|---|
| Title: | Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study) |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/eye.2017.75 |
| Publisher version: | http://doi.org/10.1038/eye.2017.75 |
| Language: | English |
| Additional information: | © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Ophthalmology, INTRAVITREAL BEVACIZUMAB AVASTIN, RETINAL-DETACHMENT, PREOPERATIVE ADJUNCT, VITREOUS HEMORRHAGE, RETINOPATHY, INJECTION, OUTCOMES |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1557053 |
Archive Staff Only
 |
View Item |
